EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19

Neil R Aggarwal iD, Jacquie Nordwall, Dominique L Braun, Lucy Chung, Jordan Coslet, Tatyana Der, Nnakelu Eriobu, Adit A Ginde, Awori J Hayanga, Helene Highbarger, Mark Holodniy, Juan P Horcajada und 19 weitere

Clinical Infectious Diseases · 2024

DOI: 10.1093/cid/ciad780 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Neil R Aggarwal und 30 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: COVID-19, SARS-CoV-2, Hospitalization, Interleukin-6. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institute of Allergy and Infectious Diseases, NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Persistent mortality in adults hospitalized due to acute COVID-19 justifies pursuit of disease mechanisms and potential therapies. The aim was to evaluate which virus and host response factors were associated with mortality risk among participants in Therapeutics for Inpatients with COVID-19 (TICO/ACTIV-3) trials.

Methods

A secondary analysis of 2625 adults hospitalized for acute SARS-CoV-2 infection randomized to 1 of 5 antiviral products or matched placebo in 114 centers on 4 continents. Uniform, site-level collection of participant baseline clinical variables was performed. Research laboratories assayed baseline upper respiratory swabs for SARS-CoV-2 viral RNA and plasma for anti–SARS-CoV-2 antibodies, SARS-CoV-2 nucleocapsid antigen (viral Ag), and interleukin-6 (IL-6). Associations between factors and time to mortality by 90 days were assessed using univariate and multivariable Cox proportional hazards models.

Results

Viral Ag ≥4500 ng/L (vs <200 ng/L; adjusted hazard ratio [aHR], 2.07; 1.29–3.34), viral RNA (<35 000 copies/mL [aHR, 2.42; 1.09–5.34], ≥35 000 copies/mL [aHR, 2.84; 1.29–6.28], vs below detection), respiratory support (<4 L O2 [aHR, 1.84; 1.06–3.22]; ≥4 L O2 [aHR, 4.41; 2.63–7.39], or noninvasive ventilation/high-flow nasal cannula [aHR, 11.30; 6.46–19.75] vs no oxygen), renal impairment (aHR, 1.77; 1.29–2.42), and IL-6 >5.8 ng/L (aHR, 2.54 [1.74–3.70] vs ≤5.8 ng/L) were significantly associated with mortality risk in final adjusted analyses. Viral Ag, viral RNA, and IL-6 were not measured in real-time.

Conclusions

Baseline virus-specific, clinical, and biological variables are strongly associated with mortality risk within 90 days, revealing potential pathogen and host-response therapeutic targets for acute COVID-19 disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19SARS-CoV-2HospitalizationInterleukin-6Antiviral AgentsHumansFemaleMaleMiddle AgedAgedAdultRNA, ViralCOVID-19 Drug TreatmentAntibodies, ViralAntigens, Viral

Stichwörter der Autor:innen

acute COVID-19host responseviral factors

Substanzen

Interleukin-6Antiviral AgentsRNA, ViralAntibodies, ViralAntigens, Viral

Autor:innen und Institutionen

  • Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado School of Medicine, Aurora, Colorado, USA.
  • Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, Minnesota, USA.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • CAMRIS International (under contract no. 75N93019D00025 with National Institute of Allergy and Infectious Diseases, Department of Health and Human Services), National Institute of Health, Bethesda, Maryland, USA.
  • Velocity Clinical Research, Chula Vista, California, USA.
  • Department of General Internal Medicine, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID-Profile: Neil R Aggarwal

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIH HHS
  • NHLBI NIH HHS
  • University of Minnesota
  • NIAID NIH HHS
  • NCI NIH HHS
  • National Institutes of Health
  • National Cancer Institute

Zitieren

APA

Aggarwal, N. R., Nordwall, J., Braun, D. L., Chung, L., Coslet, J., Der, T., Eriobu, N., Ginde, A. A., Hayanga, A. J., Highbarger, H., Holodniy, M., Horcajada, J. P., Jain, M. K., Kim, K., Laverdure, S., Lundgren, J., Natarajan, V., Nguyen, H. H., Pett, S. L., …, & ACTIV-3/TICO Study Group (2024). Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciad780

Vancouver

Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, et al. Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciad780

BibTeX
@article{Aggarwal2024,
  author = {Aggarwal, Neil R and Nordwall, Jacquie and Braun, Dominique L and Chung, Lucy and Coslet, Jordan and Der, Tatyana and Eriobu, Nnakelu and Ginde, Adit A and Hayanga, Awori J and Highbarger, Helene and Holodniy, Mark and Horcajada, Juan P and Jain, Mamta K and Kim, Kami and Laverdure, Sylvain and Lundgren, Jens and Natarajan, Ven and Nguyen, Hien H and Pett, Sarah L and Phillips, Andrew and Poulakou, Garyphallia and Price, David A and Robinson, Philip and Rogers, Angela J and Sandkovsky, Uriel and Shaw-Saliba, Katy and Sturek, Jeffrey M and Trautner, Barbara W and Waters, Michael and Reilly, Cavan and ACTIV-3/TICO Study Group, ACTIV-3/TICO Study Group},
  title = {Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19},
  journal = {Clinical Infectious Diseases},
  year = {2024},
  doi = {10.1093/cid/ciad780}
}
Kostenlos starten →